Resumo

Objectives: The objective of this study was to evaluate the efficacy of using the immunosuppressant methotrexate to treat COVID-19 vaccine-related delayed onset nodules in twenty-three patients with moderate facial disfigurement unresponsive to established treatment protocols, including intralesional steroids and hyaluronidase. Introduction: DURING THE COVID-19 PANDEMIC, dermal fillers made world headlines as it was reported that patients who had cosmetic fillers experienced side effects after receiving vaccines that utilised both viral vector and mRNA technology. Materials / method: Methotrexate is a chemotherapy agent and immune system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. It is particularly used to reduce the activity of the immune system when it mistakenly attacks parts of the body, such as skin and joints, causing illness. Methotrexate is used to treat rheumatoid arthritis, psoriatic arthritis, vasculitis, systemic sclerosis, and severe psoriasis. Results: All patients successfully responded to 10 mg of methotrexate for three months and all their nodules dissipated. One patient had to stop the treatment in week ten due to moderately severe anergia. Conclusion: The treatment protocol above was submitted and accepted by peer review at both the AIDA Dermatology Conference in Abu Dhabi (May 2022) and the IMCAS World Conference in Paris (June 2022). It has changed the lives of many patients by reducing the distress caused by this condition.